Jazz Pharmaceuticals, Inc. (JAZZ) Misses Q4 EPS by 6c, Offers Guidance

February 25, 2014 4:08 PM

Jazz Pharmaceuticals, Inc. (NASDAQ: JAZZ) reported Q4 EPS of $1.72, $0.06 worse than the analyst estimate ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found